Literature DB >> 1699681

Early expression of type I K13 keratin in the progression of mouse skin papillomas.

I Gimenez-Conti1, C M Aldaz, A B Bianchi, D R Roop, T J Slaga, C J Conti.   

Abstract

The premalignant evolution of chemically induced mouse skin papillomas is characterized by dysplastic changes, aneuploidy, induction of gamma-glutamyl transpeptidase (GGT), and changes in the expression of keratins, especially differentiation-associated K1. This keratin, which is expressed in normal epidermis and early papillomas, is no longer present in more advanced dysplastic and aneuploid papillomas and in fully invasive carcinomas. More recently, it has been shown that K13, a keratin normally present in internal epithelia but not in epidermis, is aberrantly expressed in epidermal tumors. In the present study, the timing of expression of K13 and its correlation with other markers of premalignant evolution were investigated. Papillomas were induced by SENCAR mice by a single initiating dose of 20 nmol of 7,12-dimethylbenz[a]-anthracene (DMBA) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) (2 micrograms twice a week). Tumors were randomly harvested at 10, 20 and 35 weeks of promotion. K13 and K1 expression in papillomas was studied using immunoblotting and immunostaining of consecutive sections, as previously described. As expected from previous studies, the distribution of K1 in papillomas collected at 10 weeks of promotion was restricted to differentiated cells and was uniform throughout the section of the papilloma. Conversely, K13 was expressed only as small foci in 10 out of 21 papillomas (48%). Papillomas of 20 weeks were also positive for K1. Staining for K13 was positive in these papillomas with the exception of only one that was essentially negative, presenting only one small positive focus. Some of the papillomas collected at week 35 were negative for K1, but immunostaining with K13 showed uniform staining of suprabasal cells in all the papillomas studied. In all cases, immunohistochemical results were confirmed by immunoblotting with proteins extracted from 7 microns sections from each paraffin block. These results indicate that keratins K1 and K13 are coexpressed in most papillomas from 10 to 35 weeks of promotion. However, analysis of adjacent sections showed that K13 positive areas are topographically located in the K1 negative areas of the papillomas, suggesting a shift in the differentiation program from epidermal to mucosal types of keratinization. Based on these and previous studies from our laboratory, we conclude that K13 is an early marker of papillomas progression, which occurs before gross chromosomal abnormalities are present in the stem line of the tumors, and precedes dysplastic changes and the onset of GGT expression, and is probably concomitant at the individual cell level with loss of K1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699681     DOI: 10.1093/carcin/11.11.1995

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

1.  TRP63/TP63 loss accelerates skin tumorigenesis through activation of Wnt/β-catenin signaling.

Authors:  Senthilnath Lakshmanachetty; Velmurugan Balaiya; Linda K Johnson; Maranke I Koster
Journal:  J Dermatol Sci       Date:  2018-06-01       Impact factor: 4.563

Review 2.  Oncogenic regulation and function of keratins 8 and 18.

Authors:  R G Oshima; H Baribault; C Caulín
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

3.  Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors.

Authors:  Ana Villarejo; Patricia Molina-Ortiz; Yenny Montenegro; Gema Moreno-Bueno; Saleta Morales; Vanesa Santos; Tom Gridley; Mirna A Pérez-Moreno; Héctor Peinado; Francisco Portillo; Carmela Calés; Amparo Cano
Journal:  Carcinogenesis       Date:  2015-03-16       Impact factor: 4.944

Review 4.  Transgenic mice and squamous multistage skin carcinogenesis.

Authors:  K Brown; A Balmain
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

5.  Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications.

Authors:  Erika L Abel; Joe M Angel; Kaoru Kiguchi; John DiGiovanni
Journal:  Nat Protoc       Date:  2009-08-27       Impact factor: 13.491

6.  Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis.

Authors:  A B Bianchi; N M Navone; C M Aldaz; C J Conti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.

Authors:  Carlos Caulin; Thao Nguyen; Gene A Lang; Thea M Goepfert; Bill R Brinkley; Wei-Wen Cai; Guillermina Lozano; Dennis R Roop
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

8.  Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway.

Authors:  Deepti Bajpai; Spencer Mehdizadeh; Akihiko Uchiyama; Yuta Inoue; Andrew Sawaya; Andrew Overmiller; Stephen R Brooks; Kowser Hasneen; Meghan Kellett; Elisabetta Palazzo; Sei-Ichiro Motegi; Stuart H Yuspa; Christophe Cataisson; Maria I Morasso
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

9.  Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.

Authors:  Qinlong Li; Lijuan Yin; Lawrence W Jones; Gina C-Y Chu; Jason B-Y Wu; Jen-Ming Huang; Quanlin Li; Sungyong You; Jayoung Kim; Yi-Tsung Lu; Stefan Mrdenovic; Ruoxiang Wang; Michael R Freeman; Isla Garraway; Michael S Lewis; Leland W K Chung; Haiyen E Zhau
Journal:  Oncotarget       Date:  2016-12-20

10.  Loss of epidermal MCPIP1 is associated with aggressive squamous cell carcinoma.

Authors:  Weronika Szukala; Agata Lichawska-Cieslar; Roza Pietrzycka; Maria Kulecka; Izabela Rumienczyk; Michal Mikula; Iwona Chlebicka; Piotr Konieczny; Katarzyna Dziedzic; Jacek C Szepietowski; Giulia Fontemaggi; Janusz Rys; Jolanta Jura
Journal:  J Exp Clin Cancer Res       Date:  2021-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.